Dapivirine

effectively prevented human immunodeficiency virus (HIV) infection in cocultures of monocyte-derived dendritic cells and T cells, representing primary targets in sexual transmission

Also Known As:

Networked: 45 relevant articles (5 outcomes, 21 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Palanee-Phillips, Thesla: 7 articles (01/2022 - 01/2015)
2.	Baeten, Jared M: 7 articles (01/2021 - 12/2016)
3.	Bekker, Linda-Gail: 7 articles (01/2021 - 01/2015)
4.	Nel, Annalene: 7 articles (01/2021 - 06/2014)
5.	Brown, Elizabeth R: 6 articles (01/2021 - 01/2015)
6.	Hendrix, Craig W: 6 articles (01/2021 - 12/2016)
7.	van der Straten, Ariane: 6 articles (01/2021 - 01/2015)
8.	Mellors, John W: 5 articles (01/2022 - 12/2016)
9.	Parikh, Urvi M: 5 articles (01/2022 - 12/2016)
10.	Bunge, Katherine: 5 articles (01/2021 - 12/2016)

Related Diseases

1.	Infections 12/01/2016 - "There was no significant difference in efficacy of the dapivirine ring among women older than 21 years of age (hazard ratio for infection, 0.63; 95% CI, 0.41 to 0.97) and those 21 years of age or younger (hazard ratio, 0.85; 95% CI, 0.45 to 1.60; P=0.43 for treatment-by-age interaction). " 01/01/2023 - "The Ring Study demonstrated 35.1% human immunodeficiency virus type 1 (HIV-1) infection risk reduction among participants who used the Dapivirine vaginal ring-004 (DVR), whereas the Dapivirine Ring Extended Access and Monitoring (DREAM) trial, approximated a 62% risk reduction. " 01/01/2021 - "Prior trials of a 25 mg dapivirine (DPV) ring have shown a favourable safety profile and approximately 30% risk reduction of HIV-1 infection. " 11/01/2020 - "We assessed the relative risk reduction associated with levels of ring use using residual dapivirine in returned rings as a time-dependent covariate for HIV-1 infection in multivariable Cox models, including multiple exploratory analyses designed to estimate upper limits of efficacy given uncertainty in timing of HIV-1 acquisition. " 01/01/2017 - "Infection: Dapivirine ring reduces HIV acquisition."
2.	HIV Infections (HIV Infection) 01/01/2021 - "Dapivirine probably reduces the risk of acquiring HIV infection: risk ratio (RR) 0.71, (95% confidence interval (CI) 0.57 to 0.89, I2 = 0%, 2 trials, 4588 women; moderate-certainty evidence). " 01/01/2019 - "Additional studies are needed to evaluate longer periods of dapivirine VR use among BF mother-infant pairs living in regions with higher incidence of sexually transmitted HIV infection. " 09/20/2023 - "Detection of NNRTI resistance was not higher in individuals who remained on dapivirine ring >3 months after acquiring HIV infection. " 12/01/2016 - "We evaluated the safety and efficacy of extended use of a vaginal ring containing dapivirine for the prevention of HIV infection in 1959 healthy, sexually active women, 18 to 45 years of age, from seven communities in South Africa and Uganda. " 12/01/2021 - "Clinical trials have found that the dapivirine vaginal ring (DVR) is safe to use and effective at reducing women's risk of acquiring HIV infection. "
3.	Human Influenza (Influenza) 09/01/2017 - "In summary, the in vitro antiviral results of dapivirine suggest it is a promising candidate for the development of the next generation of dual influenza and HIV antivirals." 09/01/2017 - "As part of our ongoing effort to develop the next generation of influenza antivirals with broad-spectrum antiviral activity and a high genetic barrier to drug resistance, in this study we report the discovery of dapivirine, an FDA-approved HIV nonnucleoside reverse transcriptase inhibitor, as a broad-spectrum antiviral against multiple strains of influenza A and B viruses with low micromolar efficacy. " 09/01/2017 - "Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses." 09/01/2008 - "Foremost among the newly described antiviral agents that may be developed into drugs are, for the treatment of human papilloma virus (HPV) infections, cPrPMEDAP; for the treatment of herpes simplex virus (HSV) infections, BAY 57-1293; for the treatment of varicella-zoster virus (VZV) infections, FV-100 (prodrug of Cf 1743); for the treatment of cytomegalovirus (CMV) infections, maribavir; for the treatment of poxvirus infections, ST-246; for the treatment of hepatitis B virus (HBV) infections, tenofovir disoproxil fumarate (TDF) (which in the meantime has already been approved in the EU); for the treatment of various DNA virus infections, the hexadecyloxypropyl (HDP) and octadecyloxyethyl (ODE) prodrugs of cidofovir; for the treatment of orthomyxovirus infections (i.e., influenza), peramivir; for the treatment of hepacivirus infections (i.e., hepatitis C), the protease inhibitors telaprevir and boceprevir, the nucleoside RNA replicase inhibitors (NRRIs) PSI-6130 and R1479, and various non-nucleoside RNA replicase inhibitors (NNRRIs); for the treatment of human immunodeficiency virus (HIV) infections, integrase inhibitors (INIs) such as elvitegravir, nucleoside reverse transcriptase inhibitors (NRTIs) such as apricitabine, non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as rilpivirine and dapivirine; and for the treatment of both HCV and HIV infections, cyclosporin A derivatives such as the non-immunosuppressive Debio-025."
4.	Disease Progression 01/01/2019 - "We examined the impact of dapivirine ring use at the time of HIV-1 acquisition on subsequent HIV-1 disease progression and responses to NNRTI-containing antiretroviral therapy (ART). " 01/01/2019 - "The acquisition of HIV-1 infection during dapivirine or placebo treatment in ASPIRE did not lead to differences in HIV-1 disease progression. " 01/01/2019 - "HIV-1 disease progression and virologic failure following initiation of ART were assessed among women who acquired HIV-1 while participating in Microbicide Trials Network-020, a randomized, placebo-controlled trial of a monthly, dapivirine vaginal ring. "
5.	HIV Seropositivity 01/01/2023 - "Participants with human immunodeficiency virus (HIV) seroconversion in The Ring Study, a phase 3 trial of dapivirine vaginal ring (DVR), or in the open-label extension trial dapivirine ring extended access and monitoring (DREAM) were offered enrollment in an observational cohort study (IPM 007) to assess clinical presentation and response to antiretroviral therapy (ART). "

Related Drugs and Biologics

1.	Anti-Infective Agents (Microbicides)
2.	Reverse Transcriptase Inhibitors
3.	Nucleosides
4.	Investigational Drugs
5.	UC-781
6.	Tenofovir (Viread)
7.	Rilpivirine (TMC-278)
8.	Anti-Retroviral Agents (Antiretroviral Agents)
9.	Antiviral Agents (Antivirals)
10.	MIV 150

Related Therapies and Procedures

1.	Female Contraceptive Devices (Vaginal Ring)
2.	Art Therapy
3.	Condoms (Condom)
4.	Injections